Literature DB >> 10408984

Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG).

U Brehm1, S J Piddlesden, M V Gardinier, C Linington.   

Abstract

We describe the epitope specificity of a panel of ten demyelinating monoclonal antibodies (mAb) that recognise the extracellular immunoglobulin-like domain of human myelin oligodendrocyte glycoprotein (hMOG(lgd)). All the mAbs bind to the surface of MOG-transfected fibroblasts as assessed in vitro by FACS and immunocytochemistry but failed to recognise overlapping 15-mer MOG peptides when assessed by ELISA. However, increasing peptide length to 25 amino acids revealed that four mAbs recognised epitopes within the amino acid sequence 63-100 of human MOG. In contrast, a non-demyelinating MOG-specific mAb recognised MOG by both ELISA and Western blotting but failed to stain MOG transfected fibroblasts. These observations suggest that assays based on the use of MOG-transfected cell lines will differentiate between pathogenic and non-pathogenic MOG-specific antibody responses in experimental models and human diseases of the nervous system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408984     DOI: 10.1016/s0165-5728(99)00010-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  27 in total

1.  Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.

Authors:  Marie Cathrin Mayer; Edgar Meinl
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

Review 2.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  White matter disease: Roles of anti-MOG antibodies in demyelinating diseases.

Authors:  Tomas Olsson
Journal:  Nat Rev Neurol       Date:  2011-04-12       Impact factor: 42.937

Review 4.  Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.

Authors:  H C von Büdingen; N Tanuma; P Villoslada; J C Ouallet; S L Hauser; C P Genain
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

5.  Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology.

Authors:  Cecilia B Marta; Alfred R Oliver; Rebecca A Sweet; Steven E Pfeiffer; Nancy H Ruddle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

6.  Myelin Oligodendrocyte Glycoprotein-IgG Contributes to Oligodendrocytopathy in the Presence of Complement, Distinct from Astrocytopathy Induced by AQP4-IgG.

Authors:  Ling Fang; Xinmei Kang; Zhen Wang; Shisi Wang; Jingqi Wang; Yifan Zhou; Chen Chen; Xiaobo Sun; Yaping Yan; Allan G Kermode; Lisheng Peng; Wei Qiu
Journal:  Neurosci Bull       Date:  2019-04-30       Impact factor: 5.203

7.  Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis.

Authors:  Eric C Klawiter; Laura Piccio; Jeri-Anne Lyons; Robert Mikesell; Kevin C O'Connor; Anne H Cross
Journal:  Arch Neurol       Date:  2010-09

8.  The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis.

Authors:  Craig S Clements; Hugh H Reid; Travis Beddoe; Fleur E Tynan; Matthew A Perugini; Terrance G Johns; Claude C A Bernard; Jamie Rossjohn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

Review 9.  Immune tolerance to myelin proteins.

Authors:  Audrey Seamons; Antoine Perchellet; Joan Goverman
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

10.  Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.

Authors:  Bernadette Pöllinger; Gurumoorthy Krishnamoorthy; Kerstin Berer; Hans Lassmann; Michael R Bösl; Robert Dunn; Helena S Domingues; Andreas Holz; Florian C Kurschus; Hartmut Wekerle
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.